PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY

Detalles Bibliográficos
Autores principales: Jabbour, E., Martinelli, G., Vignetti, M., Kantarjian, H., Gomez-Almaguer, D., Minami, Y., Dombret, H., Hennessy, M., Vorog, A., Wang, B., Ribera, J.-M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Publication Only
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430963/
http://dx.doi.org/10.1097/01.HS9.0000849904.09812.c6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430963/
http://dx.doi.org/10.1097/01.HS9.0000849904.09812.c6

Ejemplares similares